BriaCell Therapeutics (NASDAQ:BCTX) Trading Up 5.4% – Time to Buy?

BriaCell Therapeutics Corp. (NASDAQ:BCTX) was up 5.4% during mid-day trading on Wednesday . The company traded as high as $0.62 and last traded at $0.60. Approximately 623,193 shares were traded during trading, a decline of 60% from the average daily volume of 1,563,530 shares. The stock had previously closed at $0.57.

Analysts Set New Price Targets

Separately, HC Wainwright reissued a “buy” rating and set a $15.00 price objective on shares of BriaCell Therapeutics in a research note on Thursday, October 3rd.

BriaCell Therapeutics Stock Performance

The firm has a market capitalization of $21.59 million, a P/E ratio of -0.51 and a beta of 1.39. The firm has a 50 day moving average price of $0.78 and a two-hundred day moving average price of $0.98.

BriaCell Therapeutics (NASDAQ:BCTX) last released its quarterly earnings data on Monday, October 28th. The company reported ($0.07) earnings per share for the quarter, topping the consensus estimate of ($0.52) by $0.45. Equities research analysts forecast that BriaCell Therapeutics Corp. will post -0.58 earnings per share for the current fiscal year.

Institutional Trading of BriaCell Therapeutics

A hedge fund recently bought a new stake in BriaCell Therapeutics stock. Vontobel Holding Ltd. bought a new position in BriaCell Therapeutics Corp. (NASDAQ:BCTX) in the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm bought 80,000 shares of the company’s stock, valued at approximately $99,000. Vontobel Holding Ltd. owned 0.44% of BriaCell Therapeutics as of its most recent SEC filing. Hedge funds and other institutional investors own 15.42% of the company’s stock.

About BriaCell Therapeutics

BriaCell Therapeutics Corp., a clinical stage immuno-oncology company, engages in developing targeted immunotherapies to transform cancer care. Its lead candidate is Bria-IMT, a targeted cell-based immunotherapy that is being evaluated in a pivotal Phase 3 combination study for metastatic breast cancer.